Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
Lancet Respir Med 2022 Sep 02;[EPub Ahead of Print], HR Keir, MB Long, H Abo-Leyah, YH Giam, T Vadiveloo, T Pembridge, RC Hull, L Delgado, M Band, F McLaren-Neil, S Adamson, E Lahnsteiner, A Gilmour, C Hughes, BJ New, D Connell, R Dowey, H Turton, H Richardson, D Cassidy, J Cooper, J Suntharalingam, L Diwakar, P Russell, J Underwood, A Hicks, DP Dosanjh, B Sage, D Dhasmana, M Spears, AR Thompson, C Brightling, A Smith, M Patel, J George, AM Condliffe, A Shoemark, G MacLennan, JD ChalmersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.